Virax Biolabs Group Limited reports developments in immunology research and diagnostics, with a focus on immune response detection and post-acute infection syndromes. Company updates center on the in-development ViraxImmune T cell immune-profiling platform, PAIS-related conditions such as Long COVID, post-treatment Lyme disease and ME/CFS, and the ImmuneSelect research-use-only product portfolio.
Recurring news themes include clinical study activity, research collaborations, regulatory and quality-system preparation, commercial planning for immune-profiling products, private placements and other capital-structure actions. Updates also cover board composition, shareholder communications and Nasdaq listing-compliance matters for the company’s ordinary shares.
Virax Biolabs Group Limited (Nasdaq: VRAX) completed its initial public offering (IPO), trading began on the Nasdaq Capital Market on July 21, 2022. The IPO included 1,350,000 shares at $5.00 each, raising total gross proceeds of $6.75 million. Boustead Securities, LLC acted as the underwriter for this offering. The funds are expected to support the development of their proprietary T-Cell Test technology aimed at diagnosing viral diseases, particularly COVID-19 and other viral threats.